<DOC>
	<DOC>NCT01511185</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months Body Mass Index (BMI): 2435 kg/m^2 inclusive SUBJECTS WITH TYPE 2 DIABETES Receipt of any investigational drug within three months prior to this trial Recurrent severe hypoglycemia as judged by the investigator Cardiac disease Use of any drug (except an OAD (oral antidiabetic drug)) that in the investigator's opinion could interfere with the blood glucose level Haemoglobin maximum 10 g/L HbA1c above 12% Loss of more than 400 mL blood during the 3 months prior to trial start HEALTHY SUBJECTS Receipt of any investigational drug within 3 months prior to this trial Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram) Use of any drug that in the investigator's opinion could interfere with the blood glucose level Haemoglobin max. 10 g/L HbA1c at least 6%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>